Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK591126PMID: 37094059
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 1513857-77-6
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the clinical use of pemigatinib during breastfeeding. The manufacturer recommends that breastfeeding be discontinued during pemigatinib therapy and for 1 week after the last dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Pemigatinib
CAS Registry Number
1513857-77-6
Drug Class
Breast Feeding
Milk, Human
Antineoplastic Agents
Enzyme Inhibitors
Protein Kinase Inhibitors
Signal Transduction Inhibitors
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- [Pharmacological characteristics and clinical study results of Pemigatinib (Pemazyre(®) Tablets), a selective fibroblast growth factor receptor (FGFR) inhibitor].[Nihon Yakurigaku Zasshi. 2021][Pharmacological characteristics and clinical study results of Pemigatinib (Pemazyre(®) Tablets), a selective fibroblast growth factor receptor (FGFR) inhibitor].Kabu K, Takei S, Kondo M, Kitazawa K, Harada T. Nihon Yakurigaku Zasshi. 2021; 156(6):392-402.
- INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models.[PLoS One. 2020]INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models.Liu PCC, Koblish H, Wu L, Bowman K, Diamond S, DiMatteo D, Zhang Y, Hansbury M, Rupar M, Wen X, et al. PLoS One. 2020; 15(4):e0231877. Epub 2020 Apr 21.
- Review Futibatinib.[Drugs and Lactation Database (...]Review Futibatinib.. Drugs and Lactation Database (LactMed®). 2006
- Review Leniolisib.[Drugs and Lactation Database (...]Review Leniolisib.. Drugs and Lactation Database (LactMed®). 2006
- Review Ruxolitinib.[Drugs and Lactation Database (...]Review Ruxolitinib.. Drugs and Lactation Database (LactMed®). 2006
- Pemigatinib - Drugs and Lactation Database (LactMed®)Pemigatinib - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...